What Is Norditropin?

1. What does the label cover?

The US label, last revised in July 2025, approves Norditropin for seven uses:

Noonan syndrome, a genetic condition that often includes short stature and heart defects, is the indication that sets Norditropin apart from Genotropin, whose US label does not include it. Height SDS (standard deviation score) is height expressed as standard deviations from the average for age and sex.

The label is open about where its evidence comes from. For ISS and PWS, it says safety and effectiveness rest on trials of “another somatropin product,” and the PWS table it reproduces matches the one in Genotropin’s label. For the other five uses, Norditropin has its own trials.

2. How is Norditropin dosed?

The label sets a weekly dose for children, split into equal doses on 6 or 7 days, and a daily dose for adults (Norditropin label).

For SGA, the label suggests considering the higher dose in very short children (height SDS below −3) and older children in puberty, then reducing it if catch-up growth is strong. In children under 4 with milder shortness, it suggests starting at 0.033 mg/kg/day. Treatment for growth stops when the growth plates fuse. If growth does not pick up, especially in the first year, the label asks clinicians to check adherence and look for other causes such as hypothyroidism, poor nutrition or antibodies to GH.

Doses are guided by clinical response, side effects and IGF-1 levels for age and sex. Older adults may need lower starting doses and smaller steps, and women with normal estrogen levels or on oral estrogen may need more. Children treated for GH deficiency should be re-tested after their growth plates close before continuing on the adult dose. The general idea of stepwise changes is covered in the dose titration guide.

3. Which FlexPro pens are there?

Norditropin is a ready-to-use solution. Unlike Genotropin’s two-chamber cartridges, there is nothing to mix; the user attaches a needle, dials a dose in milligrams and injects. Each pen is single-patient use and must never be shared, even with a new needle.

PenMate is a separately dispensed accessory that hides the needle from view during the injection. Its instructions say it fits the 5, 10 and 15 mg Norditropin pens as well as the same strengths of Sogroya. The pen instructions also tell users to set the dose by the dose counter rather than by counting clicks, and to finish a dose with a new pen when the old one runs low.

Pens must not be frozen or stored right next to the refrigerator’s cooling element. The solution contains phenol as a preservative, which matters for anyone allergic to it.

4. Supply problems and discontinuations

Norditropin has had supply problems on both sides of the Atlantic. What official sources show as of November 2026:

NordiFlex was an older Novo Nordisk prefilled pen; FlexPro is the current design. The US label on DailyMed, revised before the 30 mg notice, still lists the 30 mg pen. When I checked the openFDA database in November 2026, it showed no active Norditropin shortage, only the 30 mg discontinuation. In practice, adults on higher doses who used the 30 mg pen would need the 15 mg pen or a different product, which is a prescriber’s and pharmacist’s decision.

5. What did the trials show?

The label summarizes Norditropin’s own trials (Norditropin label):

In the Noonan trial, growth during the first two years was faster on the higher dose: 10.1 and 7.6 cm/year versus 8.55 and 6.7 cm/year. A Japanese post-marketing study of 70 children with Noonan syndrome on Norditropin reported height SDS gains of about 1 and no new safety issues. One child with pre-existing cardiomyopathy died of an arrhythmia, judged unlikely to be drug-related, and the authors advise careful monitoring when Noonan syndrome comes with heart muscle disease.

Registry data

Novo Nordisk follows Norditropin users through two observational programs, NordiNet IOS and the US-based ANSWER Program. In 7,993 children with GH deficiency, those who started before age 2 gained more height (height SDS +3.2 vs +2.2 after 10 years) but had more serious adverse events (3.3% vs 0.67%) than those who started later (Rohrer et al., 2025). Among 18,405 children in the effectiveness analysis, height SDS rose 1.21 in ISS and 1.45 in GH deficiency over 10 years, with similar adverse reaction rates (Phillip et al., 2025). In adults aged 18 to 59, adverse event rates did not differ by age group, and at least 80% reached a normal IGF-1 by year 2 (Carmichael et al., 2025). These are manufacturer-sponsored studies without untreated control groups.

6. What are the side effects and warnings?

Norditropin has no boxed warning. Fluid retention dominated the adult trial (Norditropin label):

In children, the label lists headache, sore throat, ear infections and fever as most frequent in the GH-deficiency trial, with no clear differences between doses. In Turner syndrome, three girls in high-dose groups had excessive growth of the hands or feet, and two had worsening of existing scoliosis. In SGA, small dose-dependent rises in fasting glucose and insulin appeared after 1 and 2 years.

Contraindications and main warnings, shared with other somatropin brands:

• acute critical illness after heart or abdominal surgery, major trauma or respiratory failure; in two ICU trials, high-dose GH raised mortality to 42% versus 19%;
• children with PWS who are severely obese or have airway obstruction, sleep apnea or severe breathing problems, because of sudden deaths;
• active cancer, and higher risk of second tumors, especially meningiomas, in childhood cancer survivors who had head radiation;
• active proliferative or severe non-proliferative diabetic eye disease, and closed growth plates in children;
• raised pressure inside the skull, usually within 8 weeks, with an eye exam before starting and periodically after;
• falling cortisol or thyroid function after GH begins;
• slipped hip growth plate, scoliosis progression and pancreatitis in children; lipoatrophy if the same site is used repeatedly.

7. Interactions, blood sugar and GLP-1 drugs

The label warns that Norditropin may decrease insulin sensitivity, particularly at higher doses, can unmask diabetes and calls for periodic glucose checks, especially in people with existing diabetes or risk factors. The adult trial’s 5% rate of new type 2 diabetes against none on placebo, in only 53 people, shows why.

GLP-1 drugs are not named, and no trial has combined Norditropin with semaglutide or tirzepatide. Both Norditropin and the main GLP-1 brands Ozempic and Wegovy are Novo Nordisk products, but that does not mean they were tested together. For an adult with GH deficiency who also takes a GLP-1 drug, GH pushes glucose up while the GLP-1 drug pushes it down, so diabetes medicines may need adjusting when either one starts.

GH is also not a proven fix for lean-mass loss during GLP-1 weight loss. Norditropin’s adult trials enrolled people with GH deficiency and measured lean mass by total body potassium, not strength. The GLP-1 and muscle loss guide covers what is known.

8. Daily Norditropin versus weekly Sogroya

Novo Nordisk’s weekly GH, somapacitan (Sogroya), was tested against Norditropin. In the REAL 4 trial of 200 children with GH deficiency, height velocity at 52 weeks was 11.2 cm/year on weekly somapacitan versus 11.7 cm/year on Norditropin 0.034 mg/kg/day, which met noninferiority; injection site reactions were 5.3% versus 5.9% (Miller et al., 2022). A 2026 meta-analysis of 10 trials and 920 participants found no difference in height velocity (mean difference 0.12 cm/year, 95% CI −0.65 to 0.89) or adverse events, and slightly higher IGF-1 SDS on somapacitan.

Which product suits a given patient, and whether a supply problem is a reason to switch, are decisions for the treating specialist. Other weekly options are covered on the lonapegsomatropin and somatrogon pages.

9. Is Norditropin legal, and what should be recorded?

In the US, Norditropin is a prescription biologic and not a controlled substance. Growth hormone is in class S2.2.3 of the WADA 2026 Prohibited List, prohibited at all times as a non-Specified Substance.

A useful record lists the pen strength and color, the dose in milligrams, the injection site, the date each pen was first used (4 weeks refrigerated, or 3 weeks at room temperature) and the date of each IGF-1 test. During a supply change, the old and new pen should both be written down, since dose steps differ between strengths. Swelling, joint pain, hand numbness, headaches with vision changes and glucose readings belong in the same log. The peptide tracker vs spreadsheet guide covers ways to keep those records together.

10. Norditropin FAQ

• Is Norditropin the same as HGH?

  Yes. Norditropin is somatropin, recombinant human growth hormone made in E. coli. Its 191 amino acids match pituitary GH exactly. It is the hormone itself, not an analog or a releasing peptide.

• What is Norditropin approved for?

  In the US: children with growth failure from GH deficiency, short stature with Noonan syndrome, Turner syndrome, small for gestational age without catch-up growth by age 2 to 4, idiopathic short stature, or growth failure from Prader-Willi syndrome; and adults with GH deficiency. It is not approved for aging, athletic performance or weight loss.

• Was Norditropin discontinued?

  Not as a brand. The FDA drug shortage database lists the Norditropin FlexPro 30 mg/3 mL pen as to be discontinued, posted November 14, 2025. In the UK, Novo Nordisk permanently stopped NordiFlex pens and paused the 5 mg FlexPro to steady supply of the 10 mg and 15 mg pens. NordiFlex is no longer marketed in the EU.

• Is there still a Norditropin shortage?

  The European Medicines Agency marked its Norditropin FlexPro shortage resolved on December 22, 2025, after first posting it in December 2023. When checked in November 2026, the openFDA shortage database listed only the 30 mg discontinuation for Norditropin, not an active shortage.

• What is the Norditropin dose?

  The label gives weekly doses split into 6 or 7 daily injections: 0.17 to 0.24 mg/kg/week for childhood GH deficiency, 0.24 for Prader-Willi syndrome, up to 0.46 for Noonan syndrome and up to 0.47 for Turner syndrome, SGA and idiopathic short stature. Adults start near 0.2 mg/day or 0.004 mg/kg/day and are adjusted by response and IGF-1.

• How long can a Norditropin FlexPro pen be used after opening?

  After the first injection, the label allows 4 weeks in the refrigerator at 36°F to 46°F or 3 weeks at room temperature up to 77°F. Unused pens are refrigerated until the expiration date and must not be frozen.

• Can Norditropin be used with semaglutide or tirzepatide?

  No trial has studied that combination, and the label does not name GLP-1 drugs. It warns that Norditropin may decrease insulin sensitivity and that doses of insulin or other glucose-lowering drugs may need adjustment, so a combination belongs under a prescriber's supervision.

• Is Norditropin banned in sport?

  Yes. Growth hormone is in class S2.2.3 of the WADA 2026 Prohibited List, prohibited at all times, in and out of competition.

11. Sources